Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 66%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

REUTERS: Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 ...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes AmgenCVS Health Corp, a top U.S. manager of pharmacy benefits, has added new migraine drugs from Teva Pharmaceutical Industries and Eli Lilly and Co to ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

US FDA approves first biosimilar to Roche's cancer drug RituxanThe U.S. Food and Drug Administration on Wednesday approved Celltrion Inc's Truxima, making it the first biosimilar to Roche Holding AG's Rituxan ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Samsung Bioepis-Merck biosimilar to Roche's Herceptin wins FDA nodThe U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »